Evodenoson
Product Specifications
UNSPSC Description
Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α)[1].
Target Antigen
Adenosine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/evodenoson.html
Purity
99.74
Solubility
10 mM in DMSO|DMSO : 50 mg/mL (ultrasonic;warming)
Smiles
O[C@H]1[C@@H](O[C@@H]([C@H]1O)C(NC2CC2)=O)N3C4=NC(C#CCC5CCN(CC5)C(OC)=O)=NC(N)=C4N=C3
Molecular Weight
499.52
References & Citations
[1]Cavalcante IC, et al. Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74(5):2606-12.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-105017/Evodenoson-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-105017/Evodenoson-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
844873-47-8
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items